Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors, Virtual, United States (21/09/2021–21/09/2021) has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 1 European CME credit (ECMEC®). Specialists should claim only those hours of credit that are commensurate with their participation in the activity.

Through an agreement between the Union Européenne des Médecins Spécialistes and the American Medical Association, physicians may convert EACCME® credits to an equivalent number of AMA PRA Category 1 Credits™. Information on the conversion process can be found at

Live educational activities occurring outside of Canada that are recognized by the UEMS-EACCME® for ECMEC®s are deemed to be Accredited Group Learning Activities (Section 1), as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada.

Each participant can only receive the number of credits he/she is entitled to according to his/her actual participation in the event once he/she has completed the feedback form. See criteria 9 and 23 of UEMS 2016.20.

In order to help you issue individual certificates to each participant, please find below the breakdown of ECMEC®s per day: 21.09.2021 - 1.00

The EACCME® awards ECMEC®s on the basis of 1 ECMEC® for one hour of CME, with a maximum of 8 ECMEC®s per day. See Chapter X of UEMS 2016.20.

Acknowledgment of Support

This activity is supported by educational grants from Daiichi Sankyo.

Leveraging Antibody-Drug Conjugates in Cancer Care: Evolving Approaches to Bridge Clinical Gaps in Breast, GI, and Lung Tumors

Release Date: October 14, 2021
Expiration Date: October 14, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in oncology to educate oncologists regarding current and emerging antibody-drug conjugates (ADCs) for the management of lung, breast, and gastric cancer. A panel of expert faculty will review the role of HER2, HER3, and TROP2 in the development of cancer and share the most recent clinical trial data regarding ADCs, including efficacy and safety in lung, breast, and gastric cancer.
This educational activity is an archive of a live virtual symposium held on September 21, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grants from Daiichi Sankyo.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational program is directed toward a global audience of medical oncologists, pathologists, and fellows interested in the treatment of cancer. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in the treatment of patients with cancer are also invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

  • Explain the mechanistic rationale concerning the role of ADCs in solid tumors
  • Implement best practices for HER2 diagnostic testing to facilitate molecular characterization and selection of HER2-directed therapies in patients with solid tumors
  • Describe ongoing clinical trials and emerging efficacy and safety trial data on the application of novel ADCs in the treatment of patients with solid tumors
  • Formulate strategies to integrate novel ADC approaches into clinical practice for the treatment of patients with solid tumors

Faculty, Staff, and Plannrs’ Disclosures

The staff of Physicians’ Education Resource®, LLC have no relevant financial relationships with ineligible entities

Program Chair

Cristina Saura, MD, PhD
Cristina Saura, MD, PhD
Head, Breast Cancer Unit
Medical Oncology Service
Vall d’Hebron University Hospital
Barcelona, Spain

Disclosures: Consultant: Puma Biotechnology, F. Hoffmann-La Roche & Co., Pfizer Inc.


Yelena Y. Janjigian, MD
Yelena Y. Janjigian, MD
Associate Professor Chief, Gastrointestinal Oncology Service Memorial Sloan Kettering Cancer Center New York, NY

Disclosures: Grant/Research Support: NCI, Department of Defense, Cycle for Survival, Fred's Team, Rgenix, Bayer, Genentech/Roche, Bristol-Myers Squibb, Eli Lilly, Merck. Consultant: Bristol Myers Squibb, Merck Serono, Rgenix, Eli Lilly and Company, Daiichi Sankyo, Pfizer, Bayer, Imugene Ltd., Merck & Co., Zymeworks Inc., Seattle Genetics, Basilea Pharmaceutica AG Pharma, AstraZeneca. Shareholder: Rgenix (stock options).

Maurice Pérol, MD
Maurice Pérol, MD
Head of Thoracic Oncology Program
Léon Bérard Cancer Centre
Lyon, France

Disclosures: Grant/Research Support: Roche, AstraZeneca, Takeda, Boehringer Ingelheim, Chugai. Consultant: F. Hoffmann-La Roche & Co., Eli Lilly and Company, Pfizer, Boehringer Ingelheim, Clovis Oncology, Merck Sharp & Dohme, Bristol Myers Squibb, Novartis Pharmaceuticals, Pierre Fabre, AstraZeneca, Takeda, Sanofi Genzyme, Gritstone Bio, GlaxoSmithKline. Speaker’s Bureau: Eli Lilly and Company, F. Hoffmann-La Roche & Co., AstraZeneca, Pfizer Inc., Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, MSD, Takeda, Novartis Pharmaceuticals, Illumina, Inc., Chugai Pharma USA, Inc. Travel: F. Hoffmann-La Roche & Co., AstraZeneca, Pfizer Inc., Takeda.

PER® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By